SMA Combination denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sma combination are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Combination SMA Therapy as Non-Formulary

BCBS formularies are tiered drug lists that reflect the plan's contracted pricing agreements — not independent clinical judgments about what is medically appropriate for a given patient. Combination SMA therapy (two disease-modifying agents used concurrently) is frequently denied at the formulary step because one or both agents may sit on a non-preferred tier, require formulary exception review, or be listed under a specialty-drug management program with additional access requirements.

## Why This Denial Is Appealable

Federal and state law require insurers to provide a formulary exception process when a non-covered or non-preferred drug is medically necessary and no formulary alternative is clinically appropriate for the member. For SMA patients already stabilized on one agent, or those for whom the plan's preferred agent has been tried and produced inadequate response, a formulary exception grounded in the clinical record is a recognized, frequently successful pathway.

## Federal Appeal Framework

• Formulary exception request: The first step is a formal exception request, supported by a prescriber attestation that the formulary alternative is contraindicated, has been tried and failed, or is otherwise clinically inappropriate for this patient. This is separate from — and often faster than — a full internal appeal.
• Internal appeal (ACA §2719): If the exception is denied, file a Level 1 internal appeal with full supporting documentation.
• External review: After a final adverse determination, you have the right to independent external review. The federal window is generally four months from the date of the adverse determination letter; verify your exact deadline on that letter.
• Expedited track: Available when the standard timeline poses a serious health risk.

## Documentation to Gather

1. Formulary exception letter from prescriber: Specifically states why each formulary-listed SMA agent is not clinically appropriate for this patient (e.g., tried and insufficient, not indicated for this SMA type, not approved for the patient's age group — citing the FDA label, not invented facts). 2. Genetic and diagnostic records: Confirming SMA type and SMN copy number to establish which approved agents are labeled for this patient's specific indication. 3. Prior treatment history: All prior SMA therapies with dates, duration, and documented clinical response or lack thereof. 4. Functional trajectory documentation: Neurologist notes showing current motor, respiratory, and bulbar status and trend over time. 5. Current prescribing labels: Print the FDA-approved labeling for each requested agent to demonstrate the approved indication matches the patient's diagnosis exactly.

## Criteria-Mapping Structure

Request BCBS's formulary exception criteria and their SMA coverage policy. For each exception criterion:

| Exception Criterion | Supporting Evidence | |---|---| | Formulary alternative is not clinically appropriate | Prescriber letter + chart note, date: ___ | | Diagnosis matches labeled indication | Genetic report + neurology note, date: ___ | | Prior agent trial (if required) | Treatment records, dates: ___ to ___ | | Treating specialist's credentials | Neuromuscular neurologist credentials |

Attach the completed table and all referenced documents to your exception or appeal submission.